Abon Announces CLOLAR® Patent Challenge (Northvale, N.J., July 31, 2012)

Abon Pharmaceuticals, LLC, a specialty pharmaceutical company, today announced that it has filed an Abbreviated New Drug Application (ANDA), with a paragraph IV certification, with the U.S. Food and Drug Administration (FDA) seeking approval to market its Clofarabine Injection, 1 mg/ml. Abon's Clofarabine Injection is a generic equivalent of Genzyme's CLOLAR® Injection....Read More